WASHINGTON, Jan. 30 — Citing a bad case of poor judgment, an independent reviewer for the New England Journal of Medicine has conceded that he leaked privileged information to GlaxoSmithKline last May on a meta-analysis that cast the company’s diabetes drug rosiglitazone (Avandia) in a bad light.
Filed under: Avandia, News, Pharma Co. Practice, Prescription Drugs, Regulation/Government | Tagged: diabetes, Conflict of Interest, avandia, pharmaceutical companys, GSK, GlaxoSmithKline, tipping off, medical journals
